Mike Foley, a drug industry veteran and director of the Tri-Institutional Therapeutics Discovery Institute, has a pointed message for the New York life sciences industry: Don’t waste the moment. Changing the course of New York biotech has been a saga that dates back to the 1990s, and as Xconomy has detailed, progress has been made […]
NYS Entity Status
NYS Filing Date
NOVEMBER 12, 2013
NYS DOS ID#
NYS Entity Type
FOREIGN BUSINESS CORPORATION
2013 - HELSINN THERAPEUTICS (U.S.), INC.
AROUND THE WEB
- “It’s Shame On Us If We Blow It”: Highlights From NY Seizes the Momentum
By Ben Fidler - Wednesday Jun 7, 2017
- United Therapeutics in Settlement Talks With Justice Department
Thursday Jul 27, 2017
United Therapeutics has set aside $210 million for a possible settlement of a U.S. Justice Department investigation of whether the company’s contributions to patient-assistance charity groups violate federal laws against kickbacks and false claims.
- For Parkinson’s, Two New Drugs Coming As Prevail Gets Started in NY
By Ben Fidler - Wednesday Aug 9, 2017
A drug that actually slows or reverses the brain damage inflicted by Parkinson’s disease, rather than just alleviates its often debilitating symptoms, remains elusive. But Prevail Therapeutics, a startup just launched in New York, has become the latest to try. This morning, the Silverstein Foundation, a nonprofit organization formed by OrbiMed partner Jonathan Silverstein, announced […]
- Insurers Battle Families Over Costly Drug for Fatal Disease
By KATIE THOMAS - Thursday Jun 22, 2017
The case of Exondys 51 poses emotionally charged issues for families of young boys with a rare illness, who are fighting companies to get coverage for an expensive drug approved on a lower bar of proof.